111 related articles for article (PubMed ID: 9192201)
1. Reproductive toxicity testing of pharmaceutical compounds to support the inclusion of women in clinical trials.
Parkinson C; Thomas KE; Lumley CE
Hum Exp Toxicol; 1997 May; 16(5):239-46. PubMed ID: 9192201
[TBL] [Abstract][Full Text] [Related]
2. The timing of preclinical toxicological studies: pharmaceutical company approaches to toxicity testing in support of initial clinical investigations.
Parkinson C; Thomas KE; Lumley CE
Regul Toxicol Pharmacol; 1996 Apr; 23(2):162-72. PubMed ID: 8661335
[TBL] [Abstract][Full Text] [Related]
3. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
4. Reproductive toxicology guidelines: comparison and application.
Beltrame D; Mazué G
Ann Ist Super Sanita; 1993; 29(1):3-14. PubMed ID: 8129269
[TBL] [Abstract][Full Text] [Related]
5. A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.
Robinson S; Delongeas JL; Donald E; Dreher D; Festag M; Kervyn S; Lampo A; Nahas K; Nogues V; Ockert D; Quinn K; Old S; Pickersgill N; Somers K; Stark C; Stei P; Waterson L; Chapman K
Regul Toxicol Pharmacol; 2008 Apr; 50(3):345-52. PubMed ID: 18295384
[TBL] [Abstract][Full Text] [Related]
6. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase].
Kock M; Thomsen MK
Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820
[TBL] [Abstract][Full Text] [Related]
7. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
Ekimoto H
Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
[TBL] [Abstract][Full Text] [Related]
8. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
9. The nonclinical fertility study design for pharmaceuticals.
Lerman SA; Hew KW; Stewart J; Stump DG; Wise LD
Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):429-36. PubMed ID: 20025039
[TBL] [Abstract][Full Text] [Related]
10. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
Cavagnaro J; Silva Lima B
Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
[TBL] [Abstract][Full Text] [Related]
11. Animal toxicology studies on new medicines and their relationship to clinical exposure: a review of international recommendations.
Scales MD; Mahoney K
Adverse Drug React Toxicol Rev; 1991; 10(3):155-68. PubMed ID: 1747442
[TBL] [Abstract][Full Text] [Related]
12. [Recommendations Guidance of Oncology Pharmaceuticals for Reproductive Toxicity in the USA and Europe].
Suzuki N
Gan To Kagaku Ryoho; 2021 May; 48(5):627-630. PubMed ID: 34006700
[TBL] [Abstract][Full Text] [Related]
13. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization.
O'Neill RT
Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506
[TBL] [Abstract][Full Text] [Related]
14. Are women appropriately represented and assessed in clinical trials submitted for marketing authorization? A review of the database of the European Medicines Agency.
Müllner M; Vamvakas S; Rietschel M; van Zwieten-Boot BJ
Int J Clin Pharmacol Ther; 2007 Sep; 45(9):477-84. PubMed ID: 17907590
[TBL] [Abstract][Full Text] [Related]
15. Strengths and limitations of using repeat-dose toxicity studies to predict effects on fertility.
Dent MP
Regul Toxicol Pharmacol; 2007 Aug; 48(3):241-58. PubMed ID: 17512650
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of ebrotidine on reproduction. Toxicity on fertility and general reproductive performance, embryo-fetal toxicity and peri- and postnatal toxicity.
Romero A; Grau MT; Villamayor F; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):504-10. PubMed ID: 9205753
[TBL] [Abstract][Full Text] [Related]
17. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
Marchetti S; Schellens JH
Br J Cancer; 2007 Sep; 97(5):577-81. PubMed ID: 17726450
[TBL] [Abstract][Full Text] [Related]
18. Biomarker assay validation for clinical trials: a questionnaire survey to pharmaceutical companies in Japan.
Ohtsu Y; Matsumaru T; Katashima M; Kakehi M; Kakuo H; Suzuki T; Mabuchi M; Nakamura R; Nakamura T; Katori N; Tanaka S; Saito Y
Bioanalysis; 2019 Jan; 11(2):55-60. PubMed ID: 30475072
[No Abstract] [Full Text] [Related]
19. FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act.
Stevens JT; Tobia A; Lamb JC; Tellone C; O'Neal F
J Toxicol Environ Health; 1997 Apr; 50(5):415-31. PubMed ID: 9140462
[TBL] [Abstract][Full Text] [Related]
20. The disfranchisement of fertile women in clinical trials: the legal ramifications of and solutions for rectifying the knowledge gap.
Bowles LE
Vanderbilt Law Rev; 1992 May; 45(4):877-920. PubMed ID: 16047448
[No Abstract] [Full Text] [Related]
[Next] [New Search]
